Finasteride Tablet, Film Coated
Product Images NDC 68071-3234

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 68071-3234). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 3234 9

Finasteride 5 mg film-coated tablets label from NuCare Pharmaceuticals, Inc. The label indicates a quantity of 90 tablets, marked Rx Only, and warns to keep out of reach of children. It includes barcodes, patient instructions to take the medication every specified hours, and storage instructions to keep at controlled temperatures between 68-77°F. The label also provides distributor information and a reminder to refer to the manufacturer's label for the full list of ingredients.*

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

Line graph titled 'Symptom Score in a Long-Term Efficacy and Safety Study' showing mean change from baseline ± 1 SE over four years. The x-axis represents time points: Baseline, Year 1, Year 2, Year 3, and Year 4. The y-axis ranges from 0 to -6. Two lines compare symptom scores for Placebo and Finasteride groups, with Finasteride showing a greater decrease in symptom score over time. Sample sizes (n) for each group at each time point are included below the x-axis.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

A line chart titled 'Percent of Patients Having Surgery for BPH, Including TURP' showing cumulative percent of patients over 48 months. It compares two groups: Finasteride and Placebo. The Placebo group has a higher cumulative percentage of patients undergoing surgery than the Finasteride group throughout the observation period. A table below the chart lists cumulative events and number at risk per year for both groups at various time points.*

FDA Label Image

Figure 4 Prostate Volume In A Long-term Efficacy And Safety Study (Finasteride Fig3)

A line graph titled 'Prostate Volume in a Long-Term Efficacy and Safety Study' showing mean percent change from baseline in prostate volume over four years for placebo and finasteride groups. The placebo group shows an increasing trend in prostate volume, while the finasteride group shows a decreasing trend, with data points at baseline, year 1, year 2, year 3, and year 4. Sample sizes for each group at each time point are also noted.*

FDA Label Image

Figure 5 Cumulative Incidence Of A 4-point Rise In Aua Symptom Score By Treatment Group (Finasteride Fig4)

A line chart titled 'Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group' plots percent with event on the y-axis against years from randomization on the x-axis. Four treatment groups are compared: Placebo, Finasteride, Doxazosin, and Combination, each represented by differently shaped markers and lines showing event incidence over approximately 5.5 years.*

FDA Label Image

Chemical Structure (Finasteride Str)

Chemical structure of finasteride, showing its steroidal framework with attached functional groups including a ketone and tert-butyl amide moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.